Clinical Trial Update: Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a 13-valent pneumococcal conjugate vaccine in elderly subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal Conjugate Vaccine | Phase 2 | Status: COMPLETED